Dual Antigen Targeting with Talquetamab plus Teclistamab in Patients with Relapsed or Refractory Multiple Myeloma By Ogkologos - January 20, 2025 910 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the RedirecTT-1 study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Welcomes the European Parliament’s (EP) Call for a Sustainable Cancer Workforce to Deliver Quality Care for Patients with Cancer ESMO Welcomes the Inclusion of Tobacco Provisions in European Parliament’s Report on Cardiovascular Diseases and Calls for Additional Measures to Prevent Cancer Perioperative Durvalumab Continues to Show Clinical Benefit in Patients with Resectable Stage IIA to IIIB NSCLC MOST POPULAR Adjuvant Capecitabine-Containing Regimen Improves Modestly Overall Survival in Patients with Early... January 18, 2022 Safety, Tolerability and Antitumour Activity of Lorlatinib in Patients with ALK-Driven... April 7, 2023 ΚΑΡΚΙΝΟΣ ΟΡΧΕΩΝ February 10, 2019 Honeybee Venom May Be the Next Treatment for Aggressive Breast Cancer September 2, 2020 Load more HOT NEWS How My Inherited Cancer Diagnosis Has Made Me a Better Oncologist Learning to Advocate for Yourself – An Important Skill! First-Line Treatment with Atezolizumab Associated with Improved OS in Patients with... Teen With Cancer On Dream Trip To NASA Gets Surprise Call...
